reduce insulin dose when starting glp-1 receptor agonist agonists are transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are 6 Benefits of Combining Insulin
Description
Liraglutide (e.g., Saxenda): Appetite-regulating injection
Those who continued GLP-1 treatment for two or two-and-a-half years before discontinuing for the remainder of the study also gained significant risk reduction (7% and 15%, respectively)
10.1016/S0140-6736(03)12489-0 35 HatiS.PatelM.MishraB
Endocrinology 150, 11551164
Researchers identified adults who used GLP-1 receptor agonists and DPP-IV inhibitors and obtained the duration of use in the 6 years before the lag time
A dataset on formulation parameters and characteristics of drug-loaded PLGA microparticles
